In large clinical trials, all of these drugs have been found to have a direct influence on altering the course of MS. They are sometimes referred to collectively as disease-modifying therapies.
None of these treatments are a cure, and none will prevent recurring symptoms, such as fatigue or numbness. However each of them has a proven record of effectiveness. Unfortunately, no disease-modifying therapy has yet been approved to treat primary progressive MS — the type of MS that shows steady progression at onset.
The cost of disease-modifying therapies for MS varies widely, from about $20,000 to $40,000 per year. The actual cost will depend on the treatment selected, the dosage, provincial pricing, pharmacy or clinic costs, dispensing fees, etc.
The MS Society is aware that the level of reimbursement and access criteria vary from province to province and is working to ensure that people who could benefit from treatment have access.
For more information about these therapies or for other information about MS management, please contact your physician, or the nearest Multiple Sclerosis Society of Canada division office at 1-800-268-7582.
Manufacturer/Distributor & Year
of Health Canada Approval
Aubagio® Genzyme, a Sanofi company — 2013
Avonex® Biogen Idec Canada — 1998
Betaseron® Bayer HealthCare Pharmaceuticals, Inc. — 1995
Copaxone® Teva Neuroscience — 1997
Extavia® Novartis Pharmaceuticals Canada Inc. — 2009
Gilenya® Novartis Pharmaceuticals Canada Inc. — 2011
Rebif® EMD Serono Canada Inc. — 1998
Tecfidera™ Biogen Idec Canada Inc. — 2013
Tysabri® Biogen Idec Canada Inc. — 2006
» Industry-Sponsored Sites
MS One to One®
Gilenya Go Program® www.gilenya.ca
Shared Solutions® www.mswatch.ca
The drug information contained in this publication
has been obtained from the manufacturers’ product monographs.
Consult the package insert for more
detailed information about the product’s indications, contraindications,
medical use and side effects. If you are taking any of the medications
listed above, do not change the dose or stop taking your medication
without consulting your physician first.
Aubagio® is a registered trademark of Genzyme, a Sanofi company
Avonex® is a registered trademark of Biogen Idec Canada Inc.
Betaplus® is a registered trademark of Bayer HealthCare Pharmaceuticals
Betaseron® is a registered trademark of Bayer HealthCare Pharmaceuticals
Biogen Idec ONE™ Program is a registered trademark of Biogen Idec Canada Inc.
Copaxone® is a registered trademark of Teva Neuroscience
Extavia® is a registered trademark of Novartis Pharmaceuticals Canada Inc.
Gilenya® is a registered trademark of Novartis Pharmaceuticals Canada Inc.
Gilenya GO Program® is a registered trademark of Novartis Pharmaceuticals Canada Inc.
Rebif® is a registered trademark of EMD Serono Canada Inc.
MS One to One® is a registered trademark of Genzyme, a Sanofi company
Multiple Support Program® is a registered trademark of EMD Serono Canada Inc.
Shared Solutions® is a registered trademark of Teva Neuroscience
Tecfidera™ is a registered trademark of Biogen Idec Canada Inc.
Tysabri® is a registered trademark of Biogen Idec Canada Inc. and Elan Pharmaceuticals